Healthcare
•3762 stocks
•
Total Market Cap: Loading...
Nov 04, 2025
|
Tonix Partners with Massachusetts General Hospital to Launch Phase 2 Trial of TNX‑1500 for Kidney Transplant Rejection
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3762)
| Company | Market Cap | Price |
|---|---|---|
|
PROF
Profound Medical Corp.
System uses real-time MRI guidance, placing imaging at the core of its ablation therapy.
|
$146.98M |
$5.88
-1.26%
|
|
NKTX
Nkarta, Inc.
Nkarta is developing allogeneic CAR NK cell therapy (NKX019) for autoimmune diseases, directly fitting the Cell Therapy product category.
|
$146.88M |
$1.99
-4.11%
|
|
FATE
Fate Therapeutics, Inc.
Fate develops oncology-focused immunotherapies, aligning with Biotech - Oncology.
|
$144.44M |
$1.21
-4.37%
|
|
ARAY
Accuray Incorporated
Accuray's CyberKnife and TomoTherapy/Radixact systems rely on advanced medical imaging for planning and guidance.
|
$144.22M |
$1.38
-1.43%
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$143.99M |
$1.33
-7.64%
|
|
ACU
Acme United Corporation
SmartCompliance RFID First Aid kits indicate the company produces medical devices & biometrics-enabled safety products.
|
$143.78M |
$37.89
-0.11%
|
|
BTMD
biote Corp.
Vertical pellet therapy and related implantable products can be categorized under Medical Devices & Biometrics.
|
$143.24M |
$2.86
+1.06%
|
|
OWLT
Owlet, Inc.
Owlet sells FDA-cleared Medical Devices & Biometrics (Dream Sock and BabySat) with wearable biosensing capabilities.
|
$142.94M |
$8.46
-2.20%
|
|
ANIK
Anika Therapeutics, Inc.
Company develops and sells orthopedic devices including implants for cartilage repair and related regenerative solutions.
|
$140.83M |
$9.54
-2.90%
|
|
USGO
U.S. GoldMining Inc.
Metallurgical testwork and related lab analyses are conducted to inform processing and PEA.
|
$140.10M |
$10.87
-2.99%
|
|
VOR
Vor Biopharma Inc.
Vor Biopharma is focused on engineered cell therapies (eHSCs) and trem-cel, a cell therapy product.
|
$140.02M |
$19.72
-12.00%
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL is Tonix's lead oral small-molecule drug for fibromyalgia (cyclobenzaprine HCl sublingual), a direct product the company develops and plans to bring to market.
|
$137.37M |
$17.86
-4.75%
|
|
MOLN
Molecular Partners AG
Core focus on oncology therapeutics built on the DARPin platform.
|
$135.60M |
$3.81
-6.73%
|
|
SGMO
Sangamo Therapeutics, Inc.
Core platform enabling genomic medicine via gene therapy and genome regulation (ZF/ZFR) technology.
|
$134.84M |
$0.56
-3.67%
|
|
CYBN
Cybin Inc.
Company's pipeline focuses on neuropsychiatric drug development (MDD, GAD) with CYB003/CYB004.
|
$134.61M |
$6.33
-6.02%
|
|
SEER
Seer, Inc.
SP100 instrument and related proteomics hardware qualify as Diagnostic Equipment.
|
$133.63M |
$2.12
-6.61%
|
|
ANIX
Anixa Biosciences, Inc.
CER-T CAR-T therapy is a direct cell therapy product focused on oncology.
|
$133.35M |
$3.94
-4.83%
|
|
MCRB
Seres Therapeutics, Inc.
SER-155 is a cultivated live biotherapeutic product (cell therapy) comprising a defined bacterial consortium.
|
$133.08M |
$14.51
-4.82%
|
|
SPRO
Spero Therapeutics, Inc.
Tebipenem HBr is an oral small-molecule antibiotic, which is the lead product and central to Spero’s current business focus.
|
$133.07M |
$2.35
-1.05%
|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is developed as an Alzheimer's disease therapeutic.
|
$132.05M |
$2.00
-8.26%
|
|
ACTU
Actuate Therapeutics Inc
Actuate Therapeutics is a biotech company focused on oncology with a lead product elraglusib (a GSK-3β inhibitor).
|
$131.45M |
$6.54
-2.39%
|
|
LUCD
Lucid Diagnostics Inc.
EsoCheck is a diagnostic collection device used to obtain esophageal cells for testing, aligning with Diagnostic Equipment.
|
$130.91M |
$1.09
-9.50%
|
|
ENTX
Entera Bio Ltd.
Entera Bio's N-Tab platform is a drug-delivery platform enabling oral administration of large-molecule peptides.
|
$129.08M |
$2.83
-0.35%
|
|
IRD
Opus Genetics, Inc.
Core product area: AAV-based gene therapies for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$127.67M |
$2.19
+2.10%
|
|
BNR
Burning Rock Biotech Limited
Burning Rock's brPROPHET MRD and MCED products are ctDNA-based diagnostics delivered as a liquid biopsy test.
|
$126.56M |
$12.13
-1.06%
|
|
SCLX
Scilex Holding Company
Core business focused on non-opioid pain management drugs and a pipeline of non-opioid therapies.
|
$124.16M |
$19.31
+8.12%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RaniPill is the core drug-delivery platform enabling oral administration of biologics, central to the company's offering.
|
$123.72M |
$2.37
+10.00%
|
|
VTGN
VistaGen Therapeutics, Inc.
Lead CNS pipeline focused on neuropsychiatric drug development (acute SAD, MDD) and related disorders.
|
$123.63M |
$4.08
-3.89%
|
|
APYX
Apyx Medical Corporation
APYX designs and sells medical devices (Renuvion helium plasma platform and AYON body contouring system) used in surgical procedures.
|
$120.94M |
$3.27
+2.34%
|
|
ACNT
Ascent Industries Co.
Custom manufacturing / contract manufacturing services.
|
$120.92M |
$12.04
-0.37%
|
|
SERA
Sera Prognostics, Inc.
Direct Laboratory Testing & Advisory Services provided by SERA for the PreTRM test and related diagnostic offerings.
|
$120.55M |
$3.11
-2.81%
|
Showing page 24 of 38 (3762 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
